Journal of Down Syndrome & Chromosome Abnormalities
Open Access

An Overview on Molecular Biology and Genetics of 22q11.2 Deletion Syndrome

Joseph Christine^{* *}Correspondence: Joseph Christine, Department of Molecular Biology, Heidelberg University, Germany, ,

Author info »

Introduction

Clinical aspects

The chromosome 22q11.2 region is vulnerable to meiotic chromosome improvements prompting innate contortion disorders. The best described among these is the 22q11.2 erasure disorder (22q11.2DS; velo-cardio-facial condition or DiGeorge condition. The issue is the most widely recognized among microdeletion disorders, happening in ~1/4000 live births and 1/1000 hatchlings [1]. It happens as an anew 1.5–3 million base pair (Mb) cancellation in many people albeit roughly 5% are acquired. When acquired, there is a half repeat hazard with 100% penetrance and wide expressivity. Influenced people have gentle to genuine clinical elements including regularly inborn coronary illness, immunodeficiency, immune system infection, palatal irregularities, hypocalcemia (frequently connected with hypoparathyroidism), thyroid sickness, gastrointestinal contrasts, renal abnormalities, skeletal oddities, thrombocytopenia and trademark facial elements.

Mechanism

The 22q11.2 deletion typically happens by meiotic non-allelic homologous recombination (NAHR) occasions between low duplicate rehashes on chromosome 22q11.2 named LCR22. Low duplicate rehashes are additionally alluded to as segmental duplications. There are eight LCR22s that length the 22q11.2 district named LCR22A through - H. There are four LCR22s that guide to the 3 Mb area related with the problem and they are named LCR22A, - B, - C and – D. In more than 90% of patients, the district between LCR22A-D is hemizygously erased [2]. This is alluded to as the LCR22A-D cancellation type. The 1.5 Mb cancellation between LCR22A-B is the second most normal erasure type, while the 2.0 Mb LCRA-C erasure is least incessant. LCR22A and LCR22D are the biggest in estimate and have the most homology to one another, making them great focuses for NAHR occasions. The LCR22s are made out of modules holding onto pseudogenes that framed during primate advancement by the cycles of quality duplication and quality change occasions. Each LCR22 is a mind boggling mosaic of modules that has been trying to unequivocally plan in people. This intricacy has made it really hard to distinguish the situation of chromosome breakpoints in deleted patients.

Genes on 22q11.2 that causes congenital disorders

There are 45 realized protein coding qualities, seven miRNAs and ten non-coding qualities that guide to the 3 Mb, 22q11.2 district, just as extra anticipated coding and non-coding qualities. Among the qualities planning to the LCR22A-B area is TBX1, which encodes a T-box kind of record factor. This quality has gotten a lot of consideration for a significant job in clinical parts of the problem. Heterozygous changes inside TBX1 have been recognized in patients with comparable deformities as happens in those with 22q11.2DS. Supporting this, and happening sequentially before changes in patients were found, mouse models in which Tbx1 was inactivated were created. Inactivation of one allele brought about gentle cardiovascular deformities, however inactivation of the two alleles brought about congenital fissure, thymic and parathyroid organ aplasia just as cardiovascular imperfections [3]. A progression of alleles was created with fluctuating articulation levels of Tbx1 and it was tracked down that the quality is exceptionally touchy to changes in duplicate number, like what happens when one allele is deleted in people.

Further, overexpression of human or mouse Tbx1 can hereditarily protect distortions that happen in mouse cancellation models comparable to the LCR22A-B erasure. The revelation of TBX1 as a central part in clinical parts of 22q11.2DS has permitted the investigation of hereditary pathways upstream and downstream of TBX1 required for typical undeveloped turn of events.

Phenotypic expression and 22q11.2DS

One of the most difficult components of 22q11.2DS is its phenotypic changeability, notwithstanding the way that most patients have a similar size, 3 Mb erasure. For instance, 60–70% have inherent coronary illness, which incorporates various aortic curve and additionally heart surge plot peculiarities [4]. Other normal elements incorporate split of the solid sense of taste/ velopharyngeal brokenness, endocrine anomalies including hypocalcemia, thyroid sickness and development chemical insufficiency, immunodeficiency/immune system illness, gastroenterological issues, skeletal irregularities like scoliosis, just as, neuropsychiatric and intellectual shortages. As referenced above, schizophrenia happens in 25% of people with the problem. The 22q11.2 deletions is the most widely recognized pathogenic duplicate number varieties related with schizophrenia. Regardless of this, most patients with 22q11.2DS don't foster schizophrenia.

Conclusion

Following the revelation of the 22q11.2 deletion in patients, right around 40 years prior, there is still a lot to find out with regards to atomic parts of the condition. This incorporates endeavors to decide the component of chromosome 22q11.2 erasures that could prompt advancement of further developed clinical screening techniques and understanding the qualities liable for run of the mill just as abnormal aggregates. Further, 22q11.2DS fills in as a model to see how hereditary qualities and the climate can adjust the aggregate.

References

1. Afenjar A, Moutard ML, Doummar D, Guët A, Rabier D, Vermersch AI, et al. Early neurological phenotype in 4 children with biallelic PRODH mutations. Brain Dev. 2007;29(9):547-552.
2. Bailey JA, Yavor AM, Viggiano L, Misceo D, Horvath JE, Archidiacono N, et al. Human-specific duplication and mosaic transcripts: the recent paralogous structure of chromosome 22. Am J Hum Genet. 2002;70(1):83-100.
3. Carlson C, Sirotkin H, Pandita R, Goldberg R, McKie J, Wadey R, et al. Molecular definition of 22q11 deletions in 151 velo-cardio-facial syndrome patients. Am J Hum Genet. 1997;61(3):620-629.
4. Devriendt K, Fryns JP, Mortier G, Van Thienen MN, Keymolen K. The annual incidence of DiGeorge/velocardiofacial syndrome. J Med Genet. 1998;35(9):789.